

# World Journal of *Clinical Cases*

*World J Clin Cases* 2021 September 26; 9(27): 7963-8279



## Contents

Thrice Monthly Volume 9 Number 27 September 26, 2021

## EDITORIAL

7963 *Exophiala dermatitidis**Usuda D, Higashikawa T, Hotchi Y, Usami K, Shimozaawa S, Tokunaga S, Osugi I, Katou R, Ito S, Yoshizawa T, Asako S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Oba J, Nomura T, Sugita M*

## REVIEW

7973 Gastric neuroendocrine neoplasms: A review

*Köseoglu H, Duzenli T, Sezikli M*

## MINIREVIEWS

7986 Coronavirus disease 2019 and renal transplantation

*Nassar M, Nso N, Ariyaratnam J, Sandhu J, Mohamed M, Baraka B, Ibrahim A, Alfshawy M, Zheng D, Bhangoo H, Soliman KM, Li M, Rizzo V, Daoud A*

7998 Impact of COVID-19 on liver

*Su YJ, Chang CW, Chen MJ, Lai YC*

## ORIGINAL ARTICLE

## Case Control Study

8008 Association of gestational anemia with pregnancy conditions and outcomes: A nested case-control study

*Sun Y, Shen ZZ, Huang FL, Jiang Y, Wang YW, Zhang SH, Ma S, Liu JT, Zhan YL, Lin H, Chen YL, Shi YJ, Ma LK*

## Retrospective Cohort Study

8020 Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study

*Yao SY, Liang B, Chen YY, Tang YT, Dong XF, Liu TQ*

## Retrospective Study

8027 Accuracy of ultrasonography in diagnosis of fetal central nervous system malformation

*Pang B, Pan JJ, Li Q, Zhang X*

8035 Analysis of ocular structural parameters and higher-order aberrations in Chinese children with myopia

*Li X, Hu Q, Wang QR, Feng ZQ, Yang F, Du CY*

8044 Radial nerve recovery following closed nailing of humeral shaft fractures without radial nerve exploration: A retrospective study

*Yeh KL, Liaw CK, Wu TY, Chen CP*

8051 Bridging therapy and direct mechanical thrombectomy in the treatment of cardiogenic cerebral infarction with anterior circulation macrovascular occlusion

*Ding HJ, Ma C, Ye FP, Zhang JF*

- 8061** Endu combined with concurrent chemotherapy and radiotherapy for stage IIB-IVA cervical squamous cell carcinoma patients

*Zhao FJ, Su Q, Zhang W, Yang WC, Zhao L, Gao LY*

### CASE REPORT

- 8071** Primary pancreatic paraganglioma harboring lymph node metastasis: A case report

*Jiang CN, Cheng X, Shan J, Yang M, Xiao YQ*

- 8082** Retraction of lumbar disc herniation achieved by noninvasive techniques: A case report

*Wang P, Chen C, Zhang QH, Sun GD, Wang CA, Li W*

- 8090** Mixed neuroendocrine carcinoma of the gastric stump: A case report

*Zhu H, Zhang MY, Sun WL, Chen G*

- 8097** Diploic vein as a newly treatable cause of pulsatile tinnitus: A case report

*Zhao PF, Zeng R, Qiu XY, Ding HY, Lv H, Li XS, Wang GP, Li D, Gong SS, Wang ZC*

- 8104** Acute myocardial infarction and extensive systemic thrombosis in thrombotic thrombocytopenic purpura: A case report and review of literature

*Şalaru DL, Adam CA, Marcu DTM, Şimon IV, Macovei L, Ambrosie L, Chirita E, Sascau RA, Statescu C*

- 8114** Limited thoracoplasty and free musculocutaneous flap transposition for postpneumonectomy empyema: A case report

*Huang QQ, He ZL, Wu YY, Liu ZJ*

- 8120** Paraneoplastic focal segmental glomerulosclerosis associated with gastrointestinal stromal tumor with cutaneous metastasis: A case report

*Zhou J, Yang Z, Yang CS, Lin H*

- 8127** Acute coronary syndrome with severe atherosclerotic and hyperthyroidism: A case report

*Zhu HM, Zhang Y, Tang Y, Yuan H, Li ZX, Long Y*

- 8135** Gastric cancer with calcifications: A case report

*Lin YH, Yao W, Fei Q, Wang Y*

- 8142** Value of eosinophil count in bronchoalveolar lavage fluid for diagnosis of allergic bronchopulmonary aspergillosis: A case report

*Wang WY, Wan SH, Zheng YL, Zhou LM, Zhang H, Jiang LB*

- 8147** Asymptomatic gastric adenomyoma and heterotopic pancreas in a patient with pancreatic cancer: A case report and review of the literature

*Li K, Xu Y, Liu NB, Shi BM*

- 8157** Successful treatment of gastrointestinal infection-induced septic shock using the oXiris® hemofilter: A case report

*Li Y, Ji XJ, Jing DY, Huang ZH, Duan ML*

- 8164** Streptococcal pneumonia-associated hemolytic uremic syndrome treated by T-antibody-negative plasma exchange in children: Two case reports  
*Wang XL, Du Y, Zhao CG, Wu YB, Yang N, Pei L, Wang LJ, Wang QS*
- 8171** Subclavian steal syndrome associated with Sjogren's syndrome: A case report  
*Hao LJ, Zhang J, Naveed M, Chen KY, Xiao PX*
- 8177** Metachronous mixed cellularity classical Hodgkin's lymphoma and T-cell leukemia/lymphoma: A case report  
*Dong Y, Deng LJ, Li MM*
- 8186** Duodenal perforation after organophosphorus poisoning: A case report  
*Lu YL, Hu J, Zhang LY, Cen XY, Yang DH, Yu AY*
- 8192** Surgical treatment of abnormal systemic artery to the left lower lobe: A case report  
*Zhang YY, Gu XY, Li JL, Liu Z, Lv GY*
- 8199** Madelung's disease with alcoholic liver disease and acute kidney injury: A case report  
*Wu L, Jiang T, Zhang Y, Tang AQ, Wu LH, Liu Y, Li MQ, Zhao LB*
- 8207** Anesthetic technique for awake artery malformation clipping with motor evoked potential and somatosensory evoked potential: A case report  
*Zhou HY, Chen HY, Li Y*
- 8214** Multiple hidden vessels in walled-off necrosis with high-risk bleeding: Report of two cases  
*Xu N, Zhai YQ, Li LS, Chai NL*
- 8220** Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report  
*Zhang Y, Shen JQ, Shao L, Chen Y, Lei L, Wang JL*
- 8226** Successful removal of two magnets in the small intestine by laparoscopy and colonoscopy: A case report  
*Oh RG, Lee CG, Park YN, Lee YM*
- 8232** Acute lower extremity arterial thrombosis after intraocular foreign body removal under general anesthesia: A case report and review of literature  
*Jeon S, Hong JM, Lee HJ, Kim E, Lee H, Kim Y, Ri HS, Lee JJ*
- 8242** Low-intensity extracorporeal shock wave therapy for midshaft clavicular delayed union: A case report and review of literature  
*Yue L, Chen H, Feng TH, Wang R, Sun HL*
- 8249** Treatment of bilateral granulomatous lobular mastitis during lactation with traditional Chinese medicine: A case report  
*Li ZY, Sun XM, Li JW, Liu XF, Sun ZY, Chen HH, Dong YL, Sun XH*
- 8260** Early acute fat embolism syndrome caused by femoral fracture: A case report  
*Yang J, Cui ZN, Dong JN, Lin WB, Jin JT, Tang XJ, Guo XB, Cui SB, Sun M, Ji CC*



- 8268** Combined fascia iliaca compartment block and monitored anesthesia care for geriatric patients with hip fracture: Two case reports  
*Zhan L, Zhang YJ, Wang JX*
- 8274** Bell's palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell's palsy: A case report  
*Yu BY, Cen LS, Chen T, Yang TH*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Sunil Kumar Gupta, MBBS, MD, Reader (Associate Professor), Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Gorakhpur, Gorakhpur 273008, Uttar Pradesh, India. dr.sunil\_30@yahoo.co.in

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJCC as 1.337; IF without journal self cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The WJCC's CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Ji-Hong Lin; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lai Wang.

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Thrice Monthly

**EDITORS-IN-CHIEF**

Dennis A Bloomfield, Sandro Vento, Bao-Gan Peng

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

**PUBLICATION DATE**

September 26, 2021

**COPYRIGHT**

© 2021 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



Retrospective Cohort Study

# Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study

Si-Yang Yao, Bin Liang, Yuan-Yuan Chen, Yun-Tian Tang, Xiao-Feng Dong, Tian-Qi Liu

**ORCID number:** Si-Yang Yao 0000-0001-5693-0002; Bin Liang 0000-0002-3250-3011; Yuan-Yuan Chen 0000-0002-8528-1731; Yun-Tian Tang 0000-0002-5266-4090; Xiao-Feng Dong 0000-0003-2099-2652; Tian-Qi Liu 0000-0002-8114-2566.

**Author contributions:** Liu TQ proposed the study; Yao SY and Liang B performed the research and wrote the first draft; Chen YY, Tang YT, and Dong XF collected and analyzed the data; all authors contributed to the design and interpretation of the study; and Liu TQ is the guarantor.

**Supported by** Self-financed Research Program of Health and Family Planning Commission of Guangxi Zhuang Autonomous Region, No. Z20180722.

**Institutional review board statement:** The study was reviewed and approved by The People's Hospital of Guangxi Zhuang Autonomous Region Institutional Review Board (Approval No. KY-LW-2019-4).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Si-Yang Yao, Bin Liang, Yuan-Yuan Chen, Yun-Tian Tang, Xiao-Feng Dong, Tian-Qi Liu,** Department of Hepatobiliary-Pancreatic-Splenic Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Corresponding author:** Tian-Qi Liu, PhD, Chief Doctor, Department of Hepatobiliary-Pancreatic-Splenic Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. [gxljrq@163.com](mailto:gxljrq@163.com)

## Abstract

### BACKGROUND

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. Few studies have been published on the clinical stages of recurrent HCC.

### AIM

To assess the applicability of the Barcelona Clinic Liver Cancer (BCLC) staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC.

### METHODS

The clinicopathological data of 81 patients with recurrent HCC who were admitted to the Hospital of Guangxi Zhuang Autonomous Region from January 2013 to December 2017 were collected. The patients were divided into three groups according to the BCLC staging system as follows: (1) Group A with BCLC stage A, 51 patients; (2) Group B with BCLC stage B, 14 patients; and (3) Group C with BCLC stage C, 16 patients. The median time to tumor recurrence and the median overall survival were compared.

### RESULTS

The median time to tumor recurrence in groups A, B, and C was  $16 \pm 1.5$  mo,  $10 \pm 2.8$  mo, and  $6 \pm 0.5$  mo, respectively, with a statistically significant difference among them ( $\chi^2 = 70.144$ ,  $P < 0.05$ ); no statistically significant difference was noted between group A and group B ( $\chi^2 = 2.659$ ,  $P > 0.05$ ), although there were statistically significant differences between group A and group C and between group B and group C ( $\chi^2 = 62.110$ , and  $19.972$ ,  $P < 0.05$ ). The median overall survival in groups A, B, and C were  $42 \pm 5.1$  mo,  $22 \pm 3.1$  mo, and  $13 \pm 1.8$  mo, respectively, with a statistically significant difference among them ( $\chi^2 = 38.949$ ,  $P < 0.05$ ); there were statistically significant differences between group A and group B, group A

**Conflict-of-interest statement:** All the authors have no conflict of interest related to the manuscript.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Specialty type:** Surgery

**Country/Territory of origin:** China

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): 0  
Grade D (Fair): 0  
Grade E (Poor): 0

**Received:** May 16, 2021

**Peer-review started:** May 16, 2021

**First decision:** June 15, 2021

**Revised:** June 28, 2021

**Accepted:** August 3, 2021

**Article in press:** August 3, 2021

**Published online:** September 26, 2021

**P-Reviewer:** Hann HW

**S-Editor:** Ma YJ

**L-Editor:** Wang TQ

**P-Editor:** Yuan YY



and group C, and group B and group C ( $\chi^2 = 9.577, 37.172$ , and  $7.183$ , respectively;  $P < 0.05$ ).

## CONCLUSION

There are different prognoses in recurrent HCC patients according to the BCLC staging. Therefore, BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC.

**Key Words:** Clinical stages; Recurrent hepatocellular carcinoma; Barcelona Clinic Liver Cancer staging system

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** We analyzed the clinical and pathological data of 81 patients who developed recurrent hepatocellular carcinoma (HCC), with an aim to evaluate the applicability of the Barcelona Clinic Liver Cancer (BCLC) staging system for recurrent HCC. Our results indicate that BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC.

**Citation:** Yao SY, Liang B, Chen YY, Tang YT, Dong XF, Liu TQ. Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study. *World J Clin Cases* 2021; 9(27): 8020-8026

**URL:** <https://www.wjgnet.com/2307-8960/full/v9/i27/8020.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v9.i27.8020>

## INTRODUCTION

In 2012, there were 782500 patients with newly diagnosed hepatocellular carcinoma (HCC) (ranked 6th worldwide) and 745500 patients who died (ranked 2nd worldwide) [1]. The radical treatment methods for HCC include liver transplantation, surgical resection (SR), and radiofrequency ablation (RFA). Numerous studies have shown that although many patients receive curative treatment, tumor recurrence is quite common. For very early stage HCC patients, the 5-year disease-free survival (DFS) rates are 40.7% for SR and 29.3% for radiofrequency ablation. For early stage HCC patients, the 5-year DFS rates are 50.8% for SR and 14.1% for radiofrequency ablation [2]. However, even in patients who undergo liver transplantation, the tumor recurrence rate is up to 15%-20% [3]. Therefore, how to manage recurrent HCC is important in improving overall survival. To date, there have not been criteria of clinical stages for recurrent HCC. The Barcelona Clinic Liver Cancer (BCLC) staging system is regarded as the most reasonable staging criteria for primary HCC. However, whether it is suitable for recurrent HCC remains unclear. The aim of this study was to assess the applicability of the BCLC staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC, and analyze the factors affecting the prognosis of recurrent HCC patients.

## MATERIALS AND METHODS

### Patients

Three hundred and fifty-six recurrent HCC patients who received curative hepatic resection or RFA as an initial treatment at the People's Hospital of Guangxi Zhuang Autonomous Region between January 2013 and December 2017 were considered candidates for this study. The inclusion criteria were as follows: (1) Pathological diagnosis of HCC; (2) No other malignant tumors or pregnancy-related disease, which may influence survival; (3) BCLC stage A, B, or C; (4) Child-Pugh level A or B; and (5) Complete clinicopathological data. Finally, 81 patients met these criteria and were enrolled. This study did not require approval from the institutional ethics committee or informed consent, and complied with the principles of the Declaration of Helsinki.

The patients were stratified into three groups based on BCLC criteria: A (performance status score = 1, single tumor or multiple tumors with a maximum diameter  $\leq 30$  mm and tumor number  $\leq 3$ ), B (tumor number  $> 3$  or multiple tumors with a maximum diameter  $> 30$  mm), and C (radiological evidence of vascular invasion or extrahepatic metastasis).

### **Follow-up and definition of recurrence**

All patients were regularly followed to identify recurrence by assessing the level of the tumor marker alpha-fetoprotein (AFP) or performing ultrasonography (US) or contrast-enhanced computed tomography (CT) every 3 mo in the first year after radical treatment and every 6 mo in the subsequent years thereafter. If recurrence was suspected, contrast-enhanced CT, contrast-enhanced US (CEUS), or contrast-enhanced magnetic resonance imaging (MRI) was performed to confirm the diagnosis. Recurrence was defined as: (1) Histopathological confirmation; and (2) Two or more imaging diagnoses of liver cancer.

### **Data collection**

Clinical and pathological characteristics, including age, gender, AFP, HBsAg, HBV-DNA, tumor location, liver cirrhosis, tumor cell differentiation, treatment modalities, time to recurrence from last treatment, number of recurrences, and time of survival were collected from our electronic medical records or by telephone follow-up. All the patients were given antiviral treatment once they have positive HBV-DNA according to the guidelines of prevention and treatment for chronic hepatitis B (2010 version, China)[4].

### **Statistical analysis**

Continuous variables were assessed for normality and are expressed as the mean  $\pm$  SD, and comparisons among groups were evaluated by ANOVA. Categorical variables were compared by Chi-square test or Fisher's exact test with small expected frequencies ( $< 5$ ). Survival time is presented in months. Survival curves and recurrence curves for recurrent HCC patients were analyzed by the Kaplan-Meier method and the differences were analyzed by the log-rank test. All statistical analyses were performed using SPSS for Windows version 19.0 and  $P$  values  $< 0.05$  were considered significant.

## **RESULTS**

### **Baseline data comparison**

We identified 81 patients, and all of them underwent a complete follow-up. The follow-up time ranged from 2 to 65 mo, with an average follow-up time of  $23 \pm 15$  mo. There were 72 males and 9 females, with a mean age of 53 years (range, 25–82 years). There were 51 cases in group A, 14 cases in group B, and 16 cases in group C. No significant differences were detected among the three groups with respect to age, gender, AFP, HBsAg, HBV-DNA, tumor location, liver cirrhosis, tumor cell differentiation, treatment modalities, time to recurrence from last treatment, or number of recurrences (Table 1).

### **Recurrence and survival**


The median time to tumor recurrence for group A, group B, and group C was  $16 \pm 1.5$  mo,  $10 \pm 2.8$  mo, and  $6 \pm 0.5$  mo, respectively, with a statistically significant difference among them ( $\chi^2 = 70.144$ ,  $P < 0.05$ ); no statistically significant difference was noted between group A and group B ( $\chi^2 = 2.659$ ,  $P > 0.05$ ), but there were statistically significant differences between group A and group C, and group B and group C ( $\chi^2 = 62.110$  and  $19.972$ , respectively,  $P < 0.05$ ) (Figure 1).

The median time of overall survival for group A, group B, and group C was  $42 \pm 5.1$  mo,  $22 \pm 3.1$  mo, and  $13 \pm 1.8$  mo, respectively, with a statistically significant difference among them ( $\chi^2 = 38.949$ ,  $P < 0.05$ ); there were statistically significant differences between group A and group B, group A and group C, and group B and group C ( $\chi^2 = 9.577$ ,  $37.172$ , and  $7.183$ , respectively,  $P < 0.05$ ) (Figure 2)

**Table 1 Comparison of clinicopathological features among the three groups**


Variable	Group A (n = 51)	Group B (n = 14)	Group C (n = 16)	$\chi^2$ value/F value	P value
Gender (male/female)	44/7	13/1	15/1	0.622	0.784
Age (yr)	54 ± 13 (33-82)	48 ± 11 (25-67)	52 ± 10 (39-67)	1.028	0.461
AFP (μg/L)	353.5 ± 104.5 (143.5-563.4)	121.9 ± 47.5 (19.2-224.6)	326.9 ± 90.6 (133.8-519.9)	0.769	0.467
HBsAg (negative/positive)	4/47	2/12	1/15	0.968	0.728
HBV-DNA (negative/positive)	39/12	7/7	8/8	5.956	0.051
Tumor location (left lobe/right lobe/both lobe)	9/37/5	0/10/4	2/9/5	7.459	0.089
Liver cirrhosis (negative/positive)	23/28	8/6	6/10	1.180	0.554
Tumor cell differentiation (well/moderate/poor)	9/32/10	4/8/2	2/10/4	1.655	0.832
Treatment modality (RFA/RFA + PEI/TACE/LR)	21/20/1/9	4/6/1/3	7/2/4/3	10.933	0.064
Time to recurrence from last treatment (mo)	26.6 ± 3.9 (18.6-34.5)	22.6 ± 4.1 (13.7-31.6)	17.3 ± 5.3 (5.9-28.5)	0.856	0.429
Number of recurrences (first/second)	43/8	10/4	11/5	2.632	0.285

Data are expressed as the mean ± SD. AFP: Alpha-fetal protein; HBsAg: Hepatitis B surface antigen; HBV-DNA: Hepatitis B virus deoxyribonucleic acid; RFA: Radiofrequency ablation; PEI: Percutaneous ethanol injection therapy; TACE: Transarterial chemoembolization; LR: Liver resection.

**Figure 1** Recurrence curve of recurrent hepatocellular carcinoma.

## DISCUSSION

Since the BCLC staging system was put forward in 1999, it has been confirmed by a large number of clinical studies and is considered to be the most reasonable liver cancer staging criteria by combining tumor status, liver function, and treatment strategies.



**Figure 2** Overall survival curve of recurrent hepatocellular carcinoma.

Recurrence is one of the most important reasons why the prognosis of HCC is difficult to improve. At present, there have been guidelines for primary liver cancer, but for recurrent liver cancer, there is still much controversy[5,6]. Some researchers consider that the treatment for recurrent HCC can refer to that for primary HCC, including repeat hepatectomy, liver transplantation, local ablation, interventional therapy, radiotherapy, and systemic therapy[7,8]. Although SR is the best treatment option for patients with HCC, the 3-year recurrence rate is still as high as 50%-70%[9]. The treatment modalities for recurrent HCC include liver transplantation, SR, RFA, transcatheter arterial chemoembolization, and targeted therapy. Several studies show that 10%-30% of recurrent HCC patients underwent repeated SR, with a 5-year survival rate of 22%-83%, which is similar to that with first time hepatectomy[10,11]. Sun *et al*[12] found that in small recurrent HCC after SR, RFA achieved a similar overall survival and disease-free survival compared with repeated SR and resulted in a shorter hospital stay. Another meta-analysis showed contrary results, reporting that the 3-year survival after repeated SR is higher than that after RFA[13]. To date, how to manage recurrent HCC patients remains confusing, and there has not been a unanimous opinion about the treatment of recurrent HCC. Therefore, it is essential to establish clinical stages for recurrent HCC, which can provide more precise and individual treatment plans for recurrent HCC patients.

Is the Barcelona Clinic Liver Cancer (BCLC) staging system applicable to recurrent HCC? In our study, the median time to tumor recurrence for group A, group B, and group C was  $16 \pm 1.5$  mo,  $10 \pm 2.8$  mo, and  $6 \pm 0.5$  mo, respectively, with a statistically significant difference among them ( $P < 0.05$ ); there was no statistically significant difference between group A and group B ( $\chi^2 = 2.659$ ,  $P > 0.05$ ), but there were statistically significant differences between group A and group C, and group B and group C ( $P < 0.05$ ). Meanwhile, the median time of overall survival for group A, group B, and group C was  $42 \pm 5.1$  mo,  $22 \pm 3.1$  mo, and  $13 \pm 1.8$  mo, respectively, with a statistically significant difference among them ( $P < 0.05$ ); there were statistically significant differences between group A and group B, group A and group C, and group B and group C ( $P < 0.05$ ). Our study showed the BCLC staging system is applicable to recurrent HCC, and there are different prognoses in recurrent HCC patients with different stages classified by BCLC, which is just similar to that for primary HCC. It is essential to formulate the standard of clinical stages for recurrent HCC, which would contribute to the development of more precise and individual treatment plans for recurrent HCC patients, and, improve the therapeutic efficacy for recurrent HCC. Our study showed as well that the regular examination and follow-up are important because they can increase the rate of early diagnosis and treatment for recurrent HCC. Further research is needed to provide a more exact staging basis for recurrent HCC.



The limitations of our study included its non-prospective nature and small cohort size, which would lead to recall bias. Therefore, there is clearly a need for larger sample, prospective, multicenter clinical trials to confirm our conclusion in the future, and it is essential to formulate a better clinical staging system for recurrent HCC.

## CONCLUSION

There are different prognoses in recurrent HCC patients with different stages classified by BCLC, which is just similar to that for primary HCC. BCLC staging system is applicable to recurrent HCC, but not precisely enough. It is essential to formulate the standard of clinical stages for recurrent HCC, which would contribute to the development of more precise and individual treatment plans for recurrent HCC patients, and, improve the therapeutic efficacy for recurrent HCC.

## ARTICLE HIGHLIGHTS

### **Research background**

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. At present, there has not been a unanimous opinion for the treatment of recurrent HCC, and clinical stages of recurrent HCC remain controversial.

### **Research motivation**

This study showed that the Barcelona Clinic Liver Cancer (BCLC) staging system is applicable to recurrent HCC, and it is essential to formulate the standard of clinical stages for recurrent HCC, which would contribute to the development of more precise and individual treatment plans for recurrent HCC patients.

### **Research objectives**

The aim of this study was to assess the applicability of the BCLC staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC.

### **Research methods**

The clinicopathological data of 81 patients with recurrent HCC were collected. The patients were divided into three groups according to the BCLC staging system as follows: (1) Group A with BCLC stage A, 51 patients; (2) Group B with BCLC stage B, 14 patients; and (3) Group C with BCLC stage C, 16 patients. The median time to tumor recurrence time and the median overall survival were compared.

### **Research results**

The median time to tumor recurrence in groups A, B, and C was  $16 \pm 1.5$  mo,  $10 \pm 2.8$  mo, and  $6 \pm 0.5$  mo, respectively, with a statistically significant difference among them; no statistically significant difference was noted between group A and group B, although there were statistically significant differences between group A and group C and between group B and group C. The median overall survival time in groups A, B, and C was  $42 \pm 5.1$  mo,  $22 \pm 3.1$  mo, and  $13 \pm 1.8$  mo, respectively, with a statistically significant difference among them; there were statistically significant differences between group A and group B, group A and group C, and group B and group C.

### **Research conclusions**

There are different prognoses in recurrent HCC patients according to the BCLC. Therefore, BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC.

### **Research perspectives**

Recurrent HCC patients with different clinical stages have different prognoses, and it is essential to formulate more precise clinical stage criteria for recurrent HCC.



## REFERENCES

- 1 **Torre LA**, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87-108 [PMID: [25651787](#) DOI: [10.3322/caac.21262](#)]
- 2 **Wang JH**, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. *J Hepatol* 2012; **56**: 412-418 [PMID: [21756858](#) DOI: [10.1016/j.jhep.2011.05.020](#)]
- 3 **Welker MW**, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. *Transpl Int* 2013; **26**: 109-118 [PMID: [22994652](#) DOI: [10.1111/j.1432-2277.2012.01562.x](#)]
- 4 **Chinese Society of Hepatology and Chinese Society of Infectious Diseases**; Chinese Medical Association. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. *Zhonghua Gan Zang Bing Za Zhi* 2011; **19**: 13-24 [PMID: [21272453](#) DOI: [10.3760/cma.j.issn.1007-3418.2011.01.007](#)]
- 5 **Saraswat VA**, Pandey G, Shetty S. Treatment algorithms for managing hepatocellular carcinoma. *J Clin Exp Hepatol* 2014; **4**: S80-S89 [PMID: [25755616](#) DOI: [10.1016/j.jceh.2014.05.004](#)]
- 6 **Zhou J**, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). *Liver Cancer* 2018; **7**: 235-260 [PMID: [30319983](#) DOI: [10.1159/000488035](#)]
- 7 **Erridge S**, Sodergren MH. The Chengdu system for recurrent hepatocellular carcinoma: A step in the right direction. *Hepatobiliary Surg Nutr* 2019; **8**: 298-300 [PMID: [31245419](#) DOI: [10.21037/hbsn.2019.01.17](#)]
- 8 **Wen T**, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital\*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. *Hepatobiliary Surg Nutr* 2018; **7**: 353-371 [PMID: [30498711](#) DOI: [10.21037/hbsn.2018.08.01](#)]
- 9 **Torzilli G**, Donadon M, Cimino M. Are Tumor Exposure and Anatomical Resection Antithetical during Surgery for Hepatocellular Carcinoma? *Liver Cancer* 2012; **1**: 177-182 [PMID: [24159582](#) DOI: [10.1159/000343831](#)]
- 10 **Chan DL**, Morris DL, Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma - a systematic review. *Surg Oncol* 2013; **22**: e23-e30 [PMID: [23535302](#) DOI: [10.1016/j.suronc.2013.02.009](#)]
- 11 **Cabibbo G**, Enea M, Attanasio M, Bruix J, Craxi A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. *Hepatology* 2010; **51**: 1274-1283 [PMID: [20112254](#) DOI: [10.1002/hep.23485](#)]
- 12 **Sun WC**, Chen IS, Liang HL, Tsai CC, Chen YC, Wang BW, Lin HS, Chan HH, Hsu PI, Tsai WL, Cheng JS. Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection. *Oncotarget* 2017; **8**: 104571-104581 [PMID: [29262662](#) DOI: [10.18632/oncotarget.21604](#)]
- 13 **Jiang H**, Wan SY, Hou H, Zhou LB, Yu ZF, Geng XP. A meta-analysis of the efficacy of re-hepatectomy and radiofrequency ablation for recurrence liver cancer. *Zhonghua Putong Waikai Zazhi* 2015; **30**: 146-149 [DOI: [10.3760/cma.j.issn.1007-631X.2015.02.018](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

